Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm

Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm

Anti-PD1 and anti-PD-L1 agents may have intrinsic and clinically relevant differences in the treatment of non-small cell lung cancer (NSCLC) patients. By reviewing currently available indirect evidence on these agents for NSCLC treatment, highlighting possible inter- and intra-class dissimilarities,...

Full description

Bibliographic Details
Main Authors: Giuseppe Luigi Banna, Ornella Cantale, Melissa Bersanelli, Marzia Del Re, Alex Friedlaender, Alessio Cortellini, Alfredo Addeo
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-07-01
Series:Oncology Reviews
Subjects:
Immune-checkpoint inhibitor
PD1
PD-L1
lung cancer
immune-related adverse events.
Online Access:https://oncologyreviews.org/site/article/view/490

Internet

https://oncologyreviews.org/site/article/view/490

Similar Items